D&D Pharmatech Inc. (KOSDAQ:347850)

Market Cap	3.25T +562.8%
Revenue (ttm)	4.30B -62.4%
Net Income	-23.55B
EPS	-547.00
Shares Out	43.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	387,307
Average Volume	493,717
Open	77,800
Previous Close	77,500
Day's Range	73,600 - 78,200
52-Week Range	15,800 - 113,700
Beta	n/a
RSI	44.63
Earnings Date	Apr 3, 2026

About D&D Pharmatech

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 347850

Financial Performance

In 2025, D&D Pharmatech's revenue was 4.30 billion, a decrease of -62.42% compared to the previous year's 11.44 billion. Losses were -23.55 billion, -17.71% less than in 2024.